Lv01
0 积分 2023-04-20 加入
Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
31分钟前
待确认
CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study
2小时前
已完结
Phase 1/2 study of CPX‐351 for patients with Int‐2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents
2小时前
已完结
A Phase 2 Trial of CPX‐351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
5小时前
已完结
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
6个月前
已完结
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes
7个月前
已完结
Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia
8个月前
已完结
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group
8个月前
已完结
皖公网安备34019202002308
